The FDA has just approved the first medical device to treat childhood attention deficit hyperactivity disorder, or ADHD.

The Monarch external Trigeminal Nerve Stimulation (eTNS) System, is indicated for patients ages 7 to 12 years old who are not currently taking prescription ADHD medication and is the first non-drug treatment for ADHD granted marketing authorization by the FDA. The treatment is only available by prescription and must be monitored by a caregiver.

The device generates a low-level electrical pulse and connects via a wire to a small trans dermal patch that adheres to a patient's forehead, just above the eyebrows. They say a patient should feel a tingling sensation on the skin.

Clinical trials have suggested that treatment may take up to 4 weeks to become evident.

CLICK HERE to read the full announcement from the FDA.